Supplementary materials: Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Cost–effectiveness of brentuximab vedotin </b><b>for the treatment of cutaneous T-cell </b><b>lymphoma</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Table A1</b>: Clinical Inputs.</li><li><b>Table A2:</b> Cost Inputs.</li><li><b>Table A3: </b>Resource utilization.</li><li><b>Table A4:</b> Utility inputs.</li></ul><p dir="ltr"><b>Aim: </b>To assess the cost–effectiveness of brentuximab vedotin (BV) versus physician’s choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. <b>Materials & methods:</b> A partitioned survival model was developed from the National Health Service perspective in England and Wales. Model inputs were informed by the ALCANZA trial, real-world UK data, published literature or clinical experts.<b> </b><b>Results:</b> Over the modeled lifetime, BV dominated physician’s choice and provided an additional 1.58 life-years and 1.09 higher quality-adjusted life years with a net cost saving of £119,565. The net monetary benefit was £152,326 using a willingness-to-pay threshold of £30,000/quality-adjusted life year. Results were robust in sensitivity and scenario analyses. <b>Conclusion:</b> BV is a highly cost-effective treatment for advanced cutaneous T-cell lymphoma.</p>